CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. (&#34;Cosmos Health&#34; or the &#34;Company&#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting

<p><strong id="dateline">CHICAGO, IL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 11, 2026 / </strong><a rel="nofollow" href="https://pr.report/lga5"><strong>Cosmos Health Inc.</strong></a><strong> ("Cosmos Health" or the "Company")</strong><a rel="nofollow" href="https://pr.report/5zI9BhPZ"><strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</strong></a>, a diversified, vertically integrated global healthcare group, today announced it is projecting <a href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-introduces-fort18-in-the-united-states-a-mens-sexual-st-1163539" rel="nofollow">Fort18<sup>&#8482;</sup></a> to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.</p><a href="https://app.accessnewswire.com/imagelibrary/bd2d994b-c38b-46fa-a4c0-c28112fc9986/1165776/fort18.jpeg" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/bd2d994b-c38b-46fa-a4c0-c28112fc9986/1165776/fort18.jpeg" style="width:420px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><p>Fort18<sup>&#8482;</sup> is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products. Formulated with a proprietary botanical blend evaluated in published clinical research, Fort18<sup>&#8482;</sup> enters the U.S. sexual health supplement category targeting men's sexual stamina and endurance. The product is expected to launch commercially in June 2026.</p><p>The Company's projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company's commercialization plans.</p><p>According to <a rel="nofollow" href="https://pr.report/lga6">Grand View Research</a>, the global sexual health supplement market was valued at $3.52 billion in 2023 and is projected to nearly double to $7.02 billion by 2030, growing at a CAGR of 10.4%. The United States stands as one of the largest individual markets globally, estimated at $965.8 million in 2023 and forecast to reach $1.93 billion by 2030, according to <a rel="nofollow" href="https://pr.report/lga7">Grand View Horizon</a>.</p><p><strong>Greg Siokas, Chief Executive Officer of Cosmos Health, stated: </strong>"Fort18<sup>&#8482;</sup> marks our entry into the U.S. men's wellness category - a large and rapidly growing market driven by increasing consumer demand for science-supported products. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution."</p><p><strong>About Cosmos Health Inc.</strong></p><p>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life<sup>&#174;</sup>, Mediterranation<sup>&#174;</sup>, bio-bebe<sup>&#174;</sup>, C-Sept<sup>&#174;</sup> and C-Scrub<sup>&#174;</sup>. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a rel="nofollow" href="https://pr.report/lga8">www.cosmoshealthinc.com</a>, <a rel="nofollow" href="https://pr.report/lga9">www.skypremiumlife.com</a>, <a rel="nofollow" href="https://pr.report/lgaa">www.cana.gr</a>, <a rel="nofollow" href="https://pr.report/lgab">www.zipdoctor.co</a>, <a rel="nofollow" href="https://pr.report/lgac">www.cloudscreen.gr</a>, as well as <a rel="nofollow" href="https://pr.report/lgad">LinkedIn</a> and <a rel="nofollow" href="https://pr.report/lgae">X</a>.</p><p>No statement made herein has been evaluated by the U.S. Food and Drug Administration. Any product described above is not intended to diagnose, treat, cure, or prevent any disease.</p><p><strong>Forward-Looking Statements</strong></p><p>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (<a rel="nofollow" href="https://pr.report/lgaf">www.sec.gov</a>). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.</p><p><strong>Investor Relations Contact:</strong></p><p>BDG Communications<br/><a rel="nofollow" href="mailto:cosm@bdgcommunications.com">cosm@bdgcommunications.com</a></p><p><strong>SOURCE</strong>: Cosmos Health Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-projects-over-3.2-million-in-incremental-annual-revenue-1165776'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1165776" width="0" height="0"/>

COSM

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

COSM projects $3.2 million revenue boost from Fort18 launch in 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. (&amp;#34;Cosmos Health&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cosmos Health Inc. plans to launch Fort18, targeting the men&#039;s sexual health market, projected to generate $3.2 million annually in the U.S. This forecast leverages a growing market and a strategic rollout, suggesting potential for significant revenue contributions over the next 12 to 18 months.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>COSM expects Fort18 to generate $3.2 million in annual U.S. revenue.</li><li>Fort18 targets men&#039;s sexual health with a proprietary blend and launches in June 2026.</li><li>The global sexual health supplement market is projected to nearly double by 2030.</li><li>The U.S. segment is expected to grow from $965.8 million to $1.93 billion by 2030.</li><li>CEO Greg Siokas emphasizes scaling distribution for substantial revenue growth.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Grand View Research (N/A)</strong>: Reports market growth can enhance COSM&#039;s sales expectations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it highlights COSM&#039;s new product launch and growth strategy, positioning the company in a lucrative market segment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Fort18&#039;s launch in June could significantly impact COSM&#039;s revenue forecasts.</li><li>The U.S. market growth in sexual health supplements may enhance investor confidence.</li><li>Successful e-commerce rollout can validate COSM&#039;s broader commercialization strategy.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Fort18 is expected to generate $3.2 million annually within 12-18 months.</li><li>The U.S. sexual health supplement market is valued at $965.8 million in 2023.</li><li>Market projected to grow to $1.93 billion by 2030.</li><li>Fort18 is part of COSM&#039;s &#039;18 Series&#039; of nutraceutical products.</li><li>Commercial launch is scheduled for June 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider COSM as a buy with potential revenue growth in the next 12 months.</p>
  </section>
</section>


<p><strong id="dateline">CHICAGO, IL / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 11, 2026 / </strong><a rel="nofollow" href="https://pr.report/lga5"><strong>Cosmos Health Inc.</strong></a><strong> ("Cosmos Health" or the "Company")</strong><a rel="nofollow" href="https://pr.report/5zI9BhPZ"><strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</strong></a>, a diversified, vertically integrated global healthcare group, today announced it is projecting <a href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-introduces-fort18-in-the-united-states-a-mens-sexual-st-1163539" rel="nofollow">Fort18<sup>&#8482;</sup></a> to generate over $3.2 million in incremental annual U.S. revenue within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.</p><a href="https://app.accessnewswire.com/imagelibrary/bd2d994b-c38b-46fa-a4c0-c28112fc9986/1165776/fort18.jpeg" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/bd2d994b-c38b-46fa-a4c0-c28112fc9986/1165776/fort18.jpeg" style="width:420px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><p>Fort18<sup>&#8482;</sup> is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products. Formulated with a proprietary botanical blend evaluated in published clinical research, Fort18<sup>&#8482;</sup> enters the U.S. sexual health supplement category targeting men's sexual stamina and endurance. The product is expected to launch commercially in June 2026.</p><p>The Company's projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company's commercialization plans.</p><p>According to <a rel="nofollow" href="https://pr.report/lga6">Grand View Research</a>, the global sexual health supplement market was valued at $3.52 billion in 2023 and is projected to nearly double to $7.02 billion by 2030, growing at a CAGR of 10.4%. The United States stands as one of the largest individual markets globally, estimated at $965.8 million in 2023 and forecast to reach $1.93 billion by 2030, according to <a rel="nofollow" href="https://pr.report/lga7">Grand View Horizon</a>.</p><p><strong>Greg Siokas, Chief Executive Officer of Cosmos Health, stated: </strong>"Fort18<sup>&#8482;</sup> marks our entry into the U.S. men's wellness category - a large and rapidly growing market driven by increasing consumer demand for science-supported products. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution."</p><p><strong>About Cosmos Health Inc.</strong></p><p>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life<sup>&#174;</sup>, Mediterranation<sup>&#174;</sup>, bio-bebe<sup>&#174;</sup>, C-Sept<sup>&#174;</sup> and C-Scrub<sup>&#174;</sup>. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a rel="nofollow" href="https://pr.report/lga8">www.cosmoshealthinc.com</a>, <a rel="nofollow" href="https://pr.report/lga9">www.skypremiumlife.com</a>, <a rel="nofollow" href="https://pr.report/lgaa">www.cana.gr</a>, <a rel="nofollow" href="https://pr.report/lgab">www.zipdoctor.co</a>, <a rel="nofollow" href="https://pr.report/lgac">www.cloudscreen.gr</a>, as well as <a rel="nofollow" href="https://pr.report/lgad">LinkedIn</a> and <a rel="nofollow" href="https://pr.report/lgae">X</a>.</p><p>No statement made herein has been evaluated by the U.S. Food and Drug Administration. Any product described above is not intended to diagnose, treat, cure, or prevent any disease.</p><p><strong>Forward-Looking Statements</strong></p><p>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (<a rel="nofollow" href="https://pr.report/lgaf">www.sec.gov</a>). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.</p><p><strong>Investor Relations Contact:</strong></p><p>BDG Communications<br/><a rel="nofollow" href="mailto:cosm@bdgcommunications.com">cosm@bdgcommunications.com</a></p><p><strong>SOURCE</strong>: Cosmos Health Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-projects-over-3.2-million-in-incremental-annual-revenue-1165776'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1165776" width="0" height="0"/>

Cosmos Health Inc. plans to launch Fort18, targeting the men's sexual health market, projected to generate $3.2 million annually in the U.S. This forecast leverages a growing market and a strategic rollout, suggesting potential for significant revenue contributions over the next 12 to 18 months.

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News